

FOR IMMEDIATE RELEASE

March 7, 2025

Listed Company Name:	Eisai Co., Ltd.
Representative:	Haruo Naito Representative Corporate Officer and CEO
Securities Code:	4523
Stock Exchange Listings:	Prime Market of the Tokyo Stock Exchange
Inquiries:	Sayoko Sasaki Vice President, Corporate Communications Phone +81-3-3817-5120

Notification Regarding Changes in Representative Corporate Officers

Eisai Co., Ltd. resolved at its Board of Directors meeting held today, 2025, to implement the following changes in its Representative Corporate Officers.

1. Appointment of New Representative Corporate Officer (effective April 1, 2025)

1) Reason for Change

In addition to management functions such as formulating and executing company-wide strategies and business plans, finances, and business development, the Representative Corporate Officer will be responsible for integrated leadership of global business, production, quality, and technology departments, etc., ensuring a solid management foundation and achieving sustainable growth.

2) Change in Representative Corporate Officer

(Newly Appointed Representative Corporate Officer)

New Job Title	Name	Current Job Title
Representative Corporate Officer, and Executive Vice President	Terushige Iike	Executive Vice President Chief Strategy and Planning Officer

3) Career Summary of Newly Appointed Representative Corporate Officer

Name:	Terushige Iike
Date of Birth:	December 20, 1963
Apr. 1986	Joined the Company
Jul. 2009	Executive Director, Budget Management, Product Creation Headquarters, CEO Office
Jun. 2010	Executive Director, Budget Management Division, Portfolio Strategy & Budget Management Department, Product Creation Headquarters
Jun. 2012	Executive Director, Corporate Strategy Department
Jun. 2012	Vice President
Jun. 2012	Corporate Strategy
Dec. 2012	President, Japan/Asia Clinical Research

Apr. 2013	Executive Director, Clinical Development
Oct. 2014	Chief Product Creation Officer, Eisai Product Creation Systems
Oct. 2014	President, Eisai R&D Management Co., Ltd.
Jun. 2015	Senior Vice President
Apr. 2016	President, Oncology Business Group
Apr. 2021	Japan and Asia Medical
Oct. 2021	President, Eisai Japan
Jun. 2023	Executive Vice President (current)
Jun. 2023	Japan business
Jun. 2024	Chief Strategy and Planning Officer (current)

Number of shares held: 15,128 shares (as of December 31, 2024)

4) Scheduled Transfer Date

April 1, 2025

2. Retirement of Representative Corporate Officer (effective June 18, 2025)

1) Change in Representative Corporate Officer

(Representative Corporate Officer Scheduled for Retirement)

Name	Current Job Title
Yasushi Okada	Representative Corporate Officer Industry Affairs, China Business, Internal Audit

* Yasushi Okada is a nominee for New Director

2) Scheduled Transfer Date

June 18, 2025

3. New Representative Corporate Officer Structure

New Representative Corporate Officer Structure after June 18, 2025, to be as follows:

Representative Corporate Officer and CEO	Haruo Naito	Current Representative Corporate Officer and CEO
Representative Corporate Officer Executive Vice President and COO	Keisuke Naito	Current Representative Corporate Officer Executive Vice President and COO, Chief Growth Officer
Representative Corporate Officer and Executive Vice President	Terushige Iike	Current Executive Vice President Chief Strategy and Planning Officer
